Daniella Yeheskely-Hayon Selected Research

tyrphostin AG957

7/2005

The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniella Yeheskely-Hayon Research Topics

Disease

4	Neoplasms (Cancer) 01/2016 - 09/2012
1	Infections 10/2017
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2013
1	Breast Neoplasms (Breast Cancer) 01/2013
1	Shock 09/2012
1	Necrosis 09/2012
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2005

Drug/Important Bio-Agent (IBA)

1	Biological ProductsIBA 10/2017
1	Complement System Proteins (Complement)IBA 01/2016
1	GoldIBA 01/2013
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2013
1	SolutionsIBA 09/2012
1	Imatinib Mesylate (Gleevec)FDA Link 07/2005
1	tyrphostin AG957IBA 07/2005
1	Adenosine Triphosphate (ATP)IBA 07/2005
1	Tyrosine Kinase InhibitorsIBA 07/2005

Therapy/Procedure

3	Therapeutics 01/2016 - 01/2013
2	Nanospheres 01/2013 - 09/2012
1	Lasers (Laser) 01/2013